Scope, Claims, and US Patent Landscape for US Drug Patent 10,350,180
What does US 10,350,180 claim in claim-set scope terms?
US 10,350,180 is a formulation patent focused on a solid-forming local anesthetic composition built around four coupled elements:
1) Active drug pair: lidocaine + tetracaine (each 4–10 wt% in independent claim 1; or combined as a eutectic mixture 4–30 wt% in claim 11)
2) Film-former matrix: polyvinyl alcohol (PVA) at 10–18 wt%
3) Water content constrained by a PVA ratio: water at 25.94–51.87 wt% with water/PVA (w/w) > 2.4 (and dependent claims push >2.5)
4) Solid-creating scaffold: dicalcium phosphate (18–36 wt%) with petrolatum (2–13 wt%) and a sorbitan emulsifier (2–6 wt%)
The independent claim 1 and claim 11 are essentially two ways to express the same formulation architecture:
- Claim 1: constrain lidocaine and tetracaine independently (each 4–10 wt%)
- Claim 11: constrain them together as a eutectic mixture (4–30 wt% total eutectic mixture)
The claim set adds narrow control levers (salt/base form, eutectic ratios, PVA molecular weight window, viscosity window, specific sorbitan species, and a “cream-to-paste/gel” presentation prior to skin application).
Core independent claims (1 and 11): full scope mapping
Claim 1: formulation with separate lidocaine and tetracaine
- Local anesthetic formulation (solid-forming) comprising:
- 4–10 wt% lidocaine
- 4–10 wt% tetracaine
- 10–18 wt% polyvinyl alcohol
- 25.94–51.87 wt% water
- 2–6 wt% emulsifying agent selected from:
- sorbitan monopalmitate, sorbitan monostearate
- 2–13 wt% petrolatum
- 18–36 wt% dicalcium phosphate
- Critical ratio requirement:
- water to polyvinyl alcohol weight ratio (w/w) > 2.4
Claim 11: formulation with eutectic mixture of lidocaine+tetracaine
- Solid-forming local anesthetic formulation comprising:
- 4–30 wt% eutectic mixture of lidocaine and tetracaine
- 10–18 wt% polyvinyl alcohol
- 25.94–51.87 wt% water
- 2–13 wt% petrolatum
- 2–6 wt% emulsifying agent selected from:
- sorbitan monopalmitate, sorbitan monostearate
- 18–36 wt% dicalcium phosphate
- Critical ratio requirement:
- water to polyvinyl alcohol weight ratio (w/w) > 2.4
Claim architecture implication for design-around
Because claim 1 fixes ranges for each component and adds a hard ratio trigger (water/PVA > 2.4), most design-arounds are not “single-ingredient swaps.” They must move at least one of:
- the PVA fraction window,
- the water fraction window,
- the water/PVA ratio,
- the emulsifier type and level (sorbitan species in 2–6 wt%),
- the dicalcium phosphate window,
- petrolatum window,
- or the lidocaine/tetracaine constraints (separate 4–10 wt% each or eutectic mixture constraints).
Dependent claims: narrowing knobs that affect infringement risk
Drug form and eutectic definition
- Claim 2: lidocaine and tetracaine each in base form
- Claim 3: lidocaine and tetracaine are in the form of a eutectic mixture
- Claim 7: eutectic mixture weight ratio 2:1 to 1:2 (lidocaine:tetracaine)
- Claim 8: eutectic mixture weight ratio about 1:1
- Claim 9: formulation comprises 7 wt% lidocaine and 7 wt% tetracaine
- Claim 17 (emulsifier-spec dependent): emulsifying agent is sorbitan monopalmitate
The claim set creates a layered “eutectic” path:
- Claim 11 already requires an eutectic mixture (4–30 wt% total).
- Claim 3 confirms eutectic mixture in the claim 1 branch.
- Claim 7 and 8 lock eutectic ratios inside defined bounds.
PVA molecular weight
- Claim 4: PVA avg mass 30,000–80,000 Da
- Claim 16: PVA avg mass 20,000–100,000 Da
These two claims establish two overlapping PVA molecular weight windows depending on which claim is asserted.
Ratio extension
- Claim 6: water/PVA > 2.5 (tightens claim 1/11’s >2.4)
- Claim 12: same tightening on the claim 11 branch
Viscosity envelope
- Claim 18: initial viscosity 47,800–828,500 cP
- Claim 19: same viscosity range, tied to claim 11 dependent
Viscosity is a second axis besides composition. If a competitor hits all wt% and ratio ranges but lands outside this viscosity window at “initial” measurement, they can avoid those dependent claims (but may still fall under broader composition independent claims).
Form/presentation prior to application
- Claim 15: initial formulation is cream, ointment, paste, viscous lotion, or gel prior to application to skin.
This is a form-factor limitation rather than an excipient limitation. It matters for claim mapping if a product is delivered as a different physical type (e.g., solid film strips, pads, or spray without a cream/gel intermediate).
Emulsifier selection
- Claim 5: emulsifying agent is sorbitan monostearate
- Claim 17: emulsifying agent is sorbitan monopalmitate
These create two separate dependent claim paths inside the same base emulsifier selection (sorbitan monopalmitate or sorbitan monostearate).
Purpose limitation
- Claim 10 and Claim 14: formulation is for local anesthesia.
Purpose limitations can be relevant in enforcement if a competitor argues an alternative use; in practice, label claims and prescribing information often decide how this element is satisfied.
Consolidated claim-element checklist (infringement mapping tool)
Element-by-element constraints across independent claims
| Element |
Claim 1 range / requirement |
Claim 11 range / requirement |
| Lidocaine |
4–10 wt% |
Eutectic mixture total 4–30 wt% (lidocaine proportion depends on eutectic ratio) |
| Tetracaine |
4–10 wt% |
Eutectic mixture total 4–30 wt% (tetracaine proportion depends on eutectic ratio) |
| PVA |
10–18 wt% |
10–18 wt% |
| Water |
25.94–51.87 wt% |
25.94–51.87 wt% |
| Water/PVA |
> 2.4 (w/w) |
> 2.4 (w/w) |
| Emulsifier |
2–6 wt% sorbitan monopalmitate OR sorbitan monostearate |
same |
| Petrolatum |
2–13 wt% |
2–13 wt% |
| Dicalcium phosphate |
18–36 wt% |
18–36 wt% |
| Solid-forming local anesthetic |
required |
required |
Most leverage-rich dependent claim filters
| Dependent feature |
Claim(s) |
| Base form actives |
Claim 2 |
| Eutectic mixture requirement (within claim 1 branch) |
Claim 3 |
| Eutectic ratio constraints (2:1 to 1:2; about 1:1) |
Claims 7–8 |
| Specific lidocaine/tetracaine exact levels |
Claim 9 (7 wt% + 7 wt%) |
| PVA MW windows |
Claims 4 (30k–80k) and 16 (20k–100k) |
| Water/PVA tightened threshold |
Claims 6 and 12 (>2.5) |
| Specific sorbitan species |
Claims 5 (monostearate) and 17 (monopalmitate) |
| Viscosity window |
Claims 18–19 (47,800–828,500 cP) |
| Initial physical form prior to skin application |
Claim 15 |
| Local anesthesia intended use |
Claims 10 and 14 |
Scope boundary analysis: what is actually “in” and “out” of the claim set?
Likely “in” (direct hit structure)
A competitor product will map tightly if it has:
- Lidocaine and tetracaine at the stated wt% ranges (or total eutectic mixture at 4–30 wt% in the claim 11 framework)
- PVA 10–18 wt% and water 25.94–51.87 wt%
- Water/PVA ratio > 2.4 (and ideally check >2.5 dependent risk)
- sorbitan monopalmitate or sorbitan monostearate at 2–6 wt%
- petrolatum 2–13 wt%
- dicalcium phosphate 18–36 wt%
- and “solid-forming” behavior on skin with a cream/ointment/paste/viscous lotion/gel intermediate
Likely “out” (easy design-around paths)
The claim set creates multiple hard constraints. Any of the following can take a formulation out of independent claim scope:
- Water/PVA ratio at or below 2.4
- Omitting dicalcium phosphate or placing it outside 18–36 wt%
- Changing emulsifier chemistry away from sorbitan monopalmitate/monostearate or moving it outside 2–6 wt%
- Removing petrolatum or moving outside 2–13 wt%
- Moving actives outside the 4–10 wt% bounds (claim 1 branch) or the total eutectic mixture outside 4–30 wt% (claim 11 branch)
- Using a fundamentally different matrix (even if it includes PVA) that breaks one of the required coupled ranges
Because the independent claims are combination-defined and ratio-defined, “minor” changes like swapping emulsifier grade or adjusting viscosity alone may not avoid independent claim coverage.
US patent landscape: what this claim set implies competitively
Without the bibliographic record for US 10,350,180 (filing date, assignee, IPC/CPC codes, listed references, and prosecution history), a complete, source-backed landscape cannot be constructed here. The claim text itself is still actionable for competitive intelligence:
The competitive field this patent targets
The claim set sits at the intersection of:
- topical/local anesthesia formulations (lidocaine/tetracaine)
- film-forming/solid-forming topical systems
- PVA-based water systems (with explicit water/PVA ratio control)
- emulsified or structured semisolid compositions using petrolatum and sorbitan surfactants
- calcium phosphate (dicalcium phosphate) as a particulate/structuring component
Landscape inference for design space mapping
A product strategy that competes in the same performance class must choose between two risk zones:
1) Direct formulation overlap risk: staying inside the claim’s compositional rectangle and ratio trigger
2) Structural divergence risk: changing at least one of the coupled anchors (dicalcium phosphate, sorbitan emulsifier, water/PVA ratio, or petrolatum) so the formulation no longer matches the claim architecture
Common “escape hatches” likely to be used by competitors
These are not statements about specific competitors; they are standard claim-avoidance moves relative to the constraints above:
- replace sorbitan species with a non-sorbitan emulsifier
- switch from dicalcium phosphate to another carrier that changes the required wt% range
- target a water/PVA ratio below 2.4
- use different film former(s) or restructure to remove the ratio-bound PVA constraint
- change the active form or eutectic ratio such that dependent claims do not read (while recognizing independent claims may still read if composition ranges match)
Practical enforcement scope: where infringement is most likely
Infringement risk concentrates around products that:
- are marketed for local anesthesia with lidocaine and tetracaine
- use PVA as a matrix component
- contain water and satisfy water/PVA ratio constraints
- include dicalcium phosphate at high wt%
- use sorbitan emulsifiers and petrolatum in the cited windows
Dependent claim coverage expands risk if the product matches:
- eutectic ratios (2:1 to 1:2; or ~1:1)
- PVA molecular weight
- measured viscosity range
- the exact physical intermediate type prior to application
Key Takeaways
- US 10,350,180 claims a specific compositional architecture for a solid-forming topical/local anesthetic using lidocaine + tetracaine, PVA, water with a hard water/PVA ratio trigger (>2.4), plus dicalcium phosphate, petrolatum, and a sorbitan emulsifier.
- The independent claims are structurally tight: they define multiple wt% ranges simultaneously and add a ratio requirement, limiting easy partial design-arounds.
- The dependent claims add enforceable filters around eutectic ratios, PVA molecular weight, viscosity, exact active levels, and physical presentation (cream/ointment/paste/viscous lotion/gel).
- Competitive differentiation is most likely to succeed by breaking at least one independent-claim anchor: water/PVA ratio, dicalcium phosphate content, sorbitan emulsifier selection/level, or PVA/water framing.
FAQs
-
Does US 10,350,180 require a eutectic mixture in the broadest claim?
No. Claim 1 allows lidocaine and tetracaine each in separate base form ranges; eutectic is explicitly required only in dependent Claim 3 and in Claim 11 (the eutectic-structured independent branch).
-
What is the most important numeric constraint to watch for design-around?
The water/PVA (w/w) ratio > 2.4 in the independent claims. Dependent claims tighten to >2.5.
-
Is dicalcium phosphate a mandatory component?
Yes, in both independent claims: 18–36 wt% dicalcium phosphate.
-
Can switching viscosity alone avoid infringement?
It may avoid dependent claim coverage tied to viscosity (47,800–828,500 cP), but it does not avoid independent claim scope if composition ranges and the water/PVA ratio still match.
-
What emulsifiers does the patent cover?
Only sorbitan monopalmitate or sorbitan monostearate, at 2–6 wt%.
References
[1] U.S. Patent 10,350,180 (claim text provided by user).
